Equillium, Inc.

NasdaqCM:EQ Stock Report

Market Cap: US$111.6m

Equillium Management

Management criteria checks 2/4

Equillium's CEO is Bruce Steel, appointed in Jan 2006, has a tenure of 20.33 years. total yearly compensation is $4.26M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 5.87% of the company’s shares, worth $6.55M. The average tenure of the management team and the board of directors is 8.3 years and 7.3 years respectively.

Key information

Bruce Steel

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage12.20%
CEO tenure20.3yrs
CEO ownership5.9%
Management average tenure8.3yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Analysis Article • Nov 10

Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel

Equillium, Inc.'s ( NASDAQ:EQ ) price-to-sales (or "P/S") ratio of 4x might make it look like a strong buy right now...
Analysis Article • Jul 18

Equillium, Inc.'s (NASDAQ:EQ) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Those holding Equillium, Inc. ( NASDAQ:EQ ) shares would be relieved that the share price has rebounded 28% in the last...
Analysis Article • Mar 31

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc. ( NASDAQ:EQ ) shareholders that were waiting for something to happen have been dealt a blow with a 47...
Analysis Article • Feb 12

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Equillium, Inc. ( NASDAQ:EQ ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...
Analysis Article • Nov 16

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Equillium, Inc. ( NASDAQ:EQ ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Sep 26

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

The Equillium, Inc. ( NASDAQ:EQ ) share price has softened a substantial 28% over the previous 30 days, handing back...
Analysis Article • Jun 16

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Unfortunately for some shareholders, the Equillium, Inc. ( NASDAQ:EQ ) share price has dived 54% in the last thirty...
Analysis Article • May 01

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 27

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

With a price-to-sales (or "P/S") ratio of 2x Equillium, Inc. ( NASDAQ:EQ ) may be sending very bullish signals at the...
Analysis Article • Aug 14

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Equillium, Inc. ( NASDAQ:EQ ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Aug 12

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

A week ago, Equillium, Inc. ( NASDAQ:EQ ) came out with a strong set of quarterly numbers that could potentially lead...
Analysis Article • May 03

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Equillium, Inc. ( NASDAQ:EQ ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 26

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 15

Equillium GAAP EPS of -$0.41 in-line

Equillium press release (NASDAQ:EQ): Q2 GAAP EPS of -$0.41 in-line. Cash, cash equivalents and short-term investments totaled $57.6 million as of June 30, 2022, compared to $68.8 million as of March 31, 2022.
Seeking Alpha • Oct 08

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium is a clinical-stage biotech company treating severe autoimmune and inflammatory disorders. CEO Bruce Steel discusses primary drug itolizumab pivotal study. Alternative to short-term, high dose steroid therapies.
Analysis Article • Mar 09

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Every investor in Equillium, Inc. ( NASDAQ:EQ ) should be aware of the most powerful shareholder groups. Large...
Analysis Article • Nov 24

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

A look at the shareholders of Equillium, Inc. (NASDAQ:EQ) can tell us which group is most powerful. Institutions often...

CEO Compensation Analysis

How has Bruce Steel's remuneration changed compared to Equillium's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$19m

Dec 31 2025US$4mUS$519k

-US$22m

Sep 30 2025n/an/a

-US$24m

Jun 30 2025n/an/a

-US$20m

Mar 31 2025n/an/a

-US$14m

Dec 31 2024US$684kUS$471k

-US$8m

Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$1mUS$455k

-US$13m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$2mUS$455k

-US$62m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$2mUS$440k

-US$39m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$782kUS$198k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$1mUS$396k

-US$26m

Compensation vs Market: Bruce's total compensation ($USD4.26M) is above average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: Bruce's compensation has increased whilst the company is unprofitable.

CEO

Bruce Steel (59 yo)

20.3yrs
Tenure
US$4,255,248
Compensation

Mr. Bruce D. Steel, CFA serves as Strategic Advisory Board at CR Group L.P. Mr. Steel is a co-founder, Chief Executive Officer of Equillium, Inc. since January 1, 2020 and serves as its Director since Marc...

Leadership Team

NamePositionTenureCompensationOwnership
Bruce Steel
Co-Founder20.3yrsUS$4.26m5.87%
$ 6.6m
Stephen Connelly
Chief Scientific Officer & President8.3yrsUS$2.70m1.57%
$ 1.8m
Christine Zedelmayer
Senior VP & COO8.3yrsUS$2.10m0.099%
$ 110.5k
Penny Tom
Senior VP of Finance & Principal Accounting Officerno datano data0%
$ 0
Michael Moore
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Snehal Naik
Chief Development Officerno datano datano data
Lisette Acevedo
Vice President of Clinical Developmentno datano datano data
8.3yrs
Average Tenure
55yo
Average Age

Experienced Management: EQ's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bruce Steel
Co-Founder9.2yrsUS$4.26m5.87%
$ 6.6m
Daniel Bradbury
Chairman of the Board9.2yrsUS$177.29k2.96%
$ 3.3m
Martha Demski
Independent Director7.7yrsUS$76.46k0.038%
$ 42.0k
Thomas Daniel
Member of Scientific & Clinical Advisory Board7yrsno datano data
Mark Pruzanski
Independent Director7.7yrsUS$63.34k0.038%
$ 42.0k
Vijay Kuchroo
Member of Scientific & Clinical Advisory Boardno datano datano data
Peter Colabuono
Director1.4yrsUS$48.96k0%
$ 0
Bruce Sands
Member of Scientific & Clinical Advisory Board1.3yrsno datano data
Barbara Troupin
Independent Director4.3yrsUS$63.96k0%
$ 0
Charles McDermott
Independent Director7.7yrsUS$61.46k0.038%
$ 42.0k
Fred Ramsdell
Member of Scientific & Clinical Advisory Boardno datano datano data
Francisco J. Quintana
Member of Scientific & Clinical Advisory Board1.3yrsno datano data
7.3yrs
Average Tenure
61.5yo
Average Age

Experienced Board: EQ's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 08:52
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Equillium, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William WoodB. Riley Securities, Inc.
Steven SeedhouseCantor Fitzgerald & Co.
Roger SongJefferies LLC